Clinical Trial Update: Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating intravenous allogeneic adipose-derived mesenchymal stem cells for safety and efficacy in severe COVID-19 pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia
• Pneumonia Due to Sars-cov-2

Drugs mentioned

• Allogeneic adult mesenchymal stem cells from expanded adipose tissue

Snippet

Sponsor: Andalusian Network for Design and Translation of Advanced Therapies | Conditions: Sars-CoV2 | Phase 1, Phase 2 | Status: COMPLETED